Verastem - Turnaroundspekulation 2016

Mal sehen, was bei dem Kurs / Kursverlauf alles passieren kann!

Pipeline:

www.verastem.com/products/

Aktueller Kurs: 1,58  +0,15  +10,49 %  in USD

schön langsam und stetig!

Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer

www.businesswire.com/news/home/20210920005200/en/

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

•Median progression-free survival (mPFS) across all patients treated with VS-6766 in combination with defactinib in the study is 23.0 months.

•11 of 24 (46%) patients treated with the combination achieved a confirmed partial response (PR). Of the 11 patients with KRAS mutant LGSOC, 7 (64%) achieved a confirmed PR.

•Combination continues to exhibit a favorable tolerability profile.

•Top-line results from the selection portion of Verastem’s registration-directed Phase 2 RAMP 201 LGSOC study expected during the first half of 2022.

finance.yahoo.com/news/...updated-investigator-153000366.html

Einige Insiderverkäufe in den letzten Tagen! Steckt mehr dahinter?
investor.verastem.com/financial-information/sec-filings

Danke für Hinweis!
Wird langsam Zeit das der Zug hier ins Rollen kommt.

1/06/2022 BVF PARTNERS LP  Bought 3.5 Million shares of Verastem Inc


money.cnn.com/quote/quote.html?symb=VSTM

MK 305 Mio. $, operative Ausgaben pro Quartal ~15 Mio. $. Cashbestand von 103 Mio. $ soll bis 2024 reichen. Nehme ich mal in Beobachtung.
investor.verastem.com/news-releases/...2021-financial-results

Mk 208 Mio. $, bei 0,60$ denke ich über einen Einstieg nach

Zahlen für Q4/21

• Umsatz 0,5 Mio. $
  
• Verlust 16,5 Mio. $
  
• Cash 100 Mio. $
  
• MK 234 Mio. $
  

-  Company Secures up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC;

- Expected Cash Runway Through 2025 to Support Continued Development and Potential Commercial Launches of VS-6766 and Defactinib

- Enrollment Complete in Selection Phase (Part A) of RAMP 201 Evaluating VS-6766 +/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer; Expect to Report Results from Part A in 2Q 2022

- Enrollment Complete in Selection Phase (Part A) of RAMP 202 Evaluating VS-6766 +/- Defactinib for the Treatment of KRAS G12V Mutant Non-Small Cell Lung Cancer; Expect to Report Results from Part A in 2H 2022

investor.verastem.com/news-releases/...ter-and-full-year-2021

Durch das Funding mit Oxford wird VSTM wieder interessanter, beobachte ich weiter, Alert bei 1,00$

ohne News

ih.advfn.com/...;width=800&vol=1&height=400&Vol=1

RBC Capital Initiates Coverage On Verastem with Outperform Rating, Announces Price Target of $5

www.benzinga.com/news/22/04/26628716/...ces-price-target-of-5

MK 194 Mio. $, bei Cash+Finanzierung = 250 Mio. $, dazu eine gute Reichweite und noch ein paar Katalysatoren in 2022

auch das Chartbild lädt aktuell meiner Meinung nach wieder zum Einstieg ein.
Sieht sehr vielversprechend aus, wenn der Newsflow positiv bleibt.

Zahlen für Q2/22

• keine Umsätze
  
• Verlust 22 Mio. $
  
• Cash 94 Mio. $
  
• MK 173 Mio. $
  

- expects that it has a cash runway until at least 2025

investor.verastem.com/news-releases/...2022-financial-results

Update

- Results of Part A of RAMP 202 Trial in KRAS G12V-Mutant NSCLC Show VS-6766 ± Defactinib Did Not Meet Criteria to Continue to Expansion Phase

investor.verastem.com/news-releases/...66-clinical-trials-and

Heftiger Ausverkauf gestern, aber dieser bietet auch Chancen.

Die MK liegt aktuell bei ca. 95 Mio. $, dass entspricht in etwa dem Q2-Cashbestand.

Zahlen für Q4/22

• keine Umsätze
  
• Verlust 17 Mio. $
  
• Cash 88 Mio. $
  
• MK 83 Mio. $
  

investor.verastem.com/news-releases/...ter-and-full-year-2022

Zahlen für Q1/23

• kein Umsatz
  
• Verlust 16 Mio. $
  
• Cash 111 Mio. $
  
• MK 81 Mio. $
  

investor.verastem.com/news-releases/...2023-financial-results

In the RAMP 201 study, treatment with the combination of avutometinib and defactinib resulted in an objective response rate (ORR) of 45% (13/29) and tumor shrinkage in 86% (25/29) of evaluable patients.

finance.yahoo.com/news/...t-verastem-oncologys-210500253.html

the reverse stock split will become effective at 5:00 p.m. Eastern Time on May 31, 2023 (the "Effective Time") and the Company expects that its common stock will open for trading on June 1, 2023 on the Nasdaq Capital Market on a split-adjusted basis under the Company’s existing trading symbol "VSTM".

finance.yahoo.com/news/...ounces-reverse-stock-131100164.html

Trotz einer solchen Meldung ein verdammt starker bzw. stabiler Kursverlauf.

1/12 RS

investor.verastem.com/news-releases/...es-reverse-stock-split

Vorbörslich -10% auf 11$

New drug combination offers ovarian cancer breakthrough

...The revolutionary treatment has been shown to significantly shrink tumours in almost half of patients with the disease

...The new treatment blocks tumour growth, helping keep the disease at bay for years. Experts said the “fantastic” and “very exciting” results from clinical trials of the drug combination, presented at the world’s largest cancer conference this weekend, showed it was “far more effective” than any available option for patients.

...The phase 2 trial, led by the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, tested the drug avutometinib alone and in combination with defactinib in 29 patients.

Trial results show almost half the patients on the new drug combination – 45% – saw their tumours shrink significantly. It proved to be almost twice as effective as the next best treatment – trametinib, which has a response rate of 26%.

www.theguardian.com/science/2023/jun/03/...ancer-breakthrough

85 Mio. $ Offering

• u.a. 7,18 Mio. neue Aktien zu je 9,75$
  

Verastem Oncology beabsichtigt, den Nettoerlös aus dem öffentlichen Angebot für:

• (i) die fortgesetzte Forschung und Entwicklung seiner Produktkandidaten
  
• (ii) die potenzielle Einführung von avutometinib und defactinib bei niedriggradigem serösem Eierstockkrebs und 
  
• (iii) das Betriebskapital und andere allgemeine Unternehmenszwecke zu verwenden

investor.verastem.com/news-releases/...illion-public-offering

• FDA gewährt Fast-Track-Benennung für die Kombination von Avutometinib und Sotorasib zur Behandlung von KRAS G12C-Mutant NSCLC

investor.verastem.com/news-releases/...esignation-combination